↓ Skip to main content

Epigenetics as they apply to the cellular and organ pathology of cancer. Forward.

Overview of attention for book
Cover of 'Epigenetics as they apply to the cellular and organ pathology of cancer. Forward.'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Impact of Genetic Targets on Cancer Therapy
  3. Altmetric Badge
    Chapter 2 Update on Clinical Trials: Genetic Targets in Breast Cancer
  4. Altmetric Badge
    Chapter 3 Impact of Genetic Targets on Cancer Therapy in Esophagogastric Cancer
  5. Altmetric Badge
    Chapter 4 Impact of genetic targets on cancer therapy: hepatocellular cancer.
  6. Altmetric Badge
    Chapter 5 Toward the Goal of Personalized Therapy in Pancreatic Cancer by Targeting the Molecular Phenotype
  7. Altmetric Badge
    Chapter 6 Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer.
  8. Altmetric Badge
    Chapter 7 Impact of Genetic Targets on Therapy in Head and Neck Squamous Cell Carcinoma
  9. Altmetric Badge
    Chapter 8 Tyrosine Kinase Targeted Treatment of Chronic Myelogenous Leukemia and Other Myeloproliferative Neoplasms
  10. Altmetric Badge
    Chapter 9 Targeted Therapy of Multiple Myeloma
  11. Altmetric Badge
    Chapter 10 Current and future trials of targeted therapies in cutaneous melanoma.
  12. Altmetric Badge
    Chapter 11 Current Approaches to Epigenetic Therapy for the Treatment of Mantle Cell Lymphoma
  13. Altmetric Badge
    Chapter 12 Impact of Genetic Targets on Primary Brain Tumor Therapy: What’s Ready for Prime Time?
  14. Altmetric Badge
    Chapter 13 Rational Therapy for Renal Cell Carcinoma Based on its Genetic Targets
  15. Altmetric Badge
    Chapter 14 Molecular and Genetic Markers of Follicular-Cell Thyroid Cancer: Etiology and Diagnostic and Therapeutic Opportunities
  16. Altmetric Badge
    Chapter 15 Genetic Targets in Pediatric Acute Lymphoblastic Leukemia
  17. Altmetric Badge
    Chapter 16 Emerging Molecular Therapies for the Treatment of Acute Lymphoblastic Leukemia
  18. Altmetric Badge
    Chapter 17 Impact of Genetic Targets on Prostate Cancer Therapy
  19. Altmetric Badge
    Chapter 18 Small-Cell Lung Cancer: An Update on Targeted Therapies
  20. Altmetric Badge
    Chapter 19 Impact of Genetic Targets on Cancer Therapy in Acute Myelogenous Leukemia
Attention for Chapter 6: Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

wikipedia
3 Wikipedia pages

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer.
Chapter number 6
Book title
Impact of Genetic Targets on Cancer Therapy
Published in
Advances in experimental medicine and biology, January 2013
DOI 10.1007/978-1-4614-6176-0_6
Pubmed ID
Book ISBNs
978-1-4614-6175-3, 978-1-4614-6176-0
Authors

Nicholas Lamparella, Amit Barochia, Salah Almokadem, Lamparella, Nicholas, Barochia, Amit, Almokadem, Salah

Abstract

Non-small cell lung cancer represents a group of heterogeneous diseases. The last decade witnessed significant progress in improving our understanding of the biology of non-small cell lung cancer, which led to the identification of several genetic targets. Those genetic targets were utilized to explain clinical phenomena, such as the occurrence of non-small cell lung cancer in never-smokers, to predict response to conventional chemotherapy and biological agents, and to explain and predict resistance to therapy. The progress in the treatment of non-small cell lung cancer in the last few years was based on a new generation of population-enriched clinical trials that utilized genetic targets such as somatic EGFR mutations and ALK-EML4 mutations. In this review we will discuss the available information about the key genetic markers of non-small cell lung cancer and the pivotal clinical trials that validate the use of those genetic markers in non-small cell lung cancer patients.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 21%
Professor > Associate Professor 3 21%
Student > Ph. D. Student 2 14%
Student > Postgraduate 2 14%
Student > Doctoral Student 1 7%
Other 1 7%
Unknown 2 14%
Readers by discipline Count As %
Medicine and Dentistry 5 36%
Biochemistry, Genetics and Molecular Biology 3 21%
Agricultural and Biological Sciences 2 14%
Unspecified 1 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Other 1 7%
Unknown 1 7%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2020.
All research outputs
#7,454,951
of 22,790,780 outputs
Outputs from Advances in experimental medicine and biology
#1,227
of 4,941 outputs
Outputs of similar age
#84,270
of 281,013 outputs
Outputs of similar age from Advances in experimental medicine and biology
#46
of 169 outputs
Altmetric has tracked 22,790,780 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,941 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,013 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 169 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.